Inify Laboratories AB

Regulatory Filings • Dec 19, 2025

Inify Laboratories - mandatory notification of trade

Inify Laboratories - mandatory notification of trade

Stockholm - 19 December 2025 - Inify Laboratories AB (publ) (the "Company")

announces that the below primary insider was allocated new shares at the

subscription price in the private placement announced by the Company on 9

December 2025 (the "Private Placement"), as further specified in the attached

notification forms:

-          Gallivant S.à r.l. and Monsun AS, companies closely associated with

board member Magne Jordanger, have been allocated 17,167,701 and 3,347,788 new

shares, respectively, in the Private Placement (in aggregate: 20,515,489 new

shares).

Gallivant S.à r.l. and Monsun AS will, subject to completion of the Private

Placement, own 64,578,361 and 11,391,684 shares, respectively, in the Company.

For further information, please contact CEO, Fredrik Palm,

fredrik.palm@inify.com, or visit https://www.inify.com.

This information is subject to the disclosure requirements in the EU Market

Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian

Securities Trading Act.

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in

histopathology, with a focus on streamlining patient pathways. The company

performs clinical diagnostics in prostate cancer and gastroenterology, providing

an integrated service that spans from early sample handling to final diagnosis.

The laboratory system is scalable both in handling large volumes of patient

samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to

tissue preparation and diagnosis - using a fully digital, standardised and AI

-assisted workflow. The diagnosis is always performed by a pathologist and is

assisted by Inify's proprietary AI, proven to have world-leading precision in

clinical evaluations. The entire workflow is supported by a tailor-made system

that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,

with local laboratories in Sweden and the UK. The company's share is listed on

Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103

-MERK) under the ticker

INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)